(Q34465347)

English

Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study (English)

1 reference

Europe PubMed Central

2 August 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Ronan T Swords

1

1 reference

Europe PubMed Central

2 August 2017

Harry P Erba

2

1 reference

Europe PubMed Central

2 August 2017

Daniel J DeAngelo

3

1 reference

Europe PubMed Central

2 August 2017

Dale L Bixby

4

1 reference

Europe PubMed Central

2 August 2017

Jessica K Altman

5

1 reference

Europe PubMed Central

2 August 2017

Michael Maris

6

1 reference

Europe PubMed Central

2 August 2017

Zhaowei Hua

7

1 reference

Europe PubMed Central

2 August 2017

Stephen J Blakemore

8

1 reference

Europe PubMed Central

2 August 2017

Hélène Faessel

9

1 reference

Europe PubMed Central

2 August 2017

Farhad Sedarati

10

1 reference

Europe PubMed Central

2 August 2017

Bruce J Dezube

11

1 reference

Europe PubMed Central

2 August 2017

Francis J Giles

12

1 reference

Europe PubMed Central

2 August 2017

Bruno C Medeiros

13

1 reference

Europe PubMed Central

2 August 2017

language of work or name

0 references

publication date

2 March 2015

1 reference

Europe PubMed Central

2 August 2017

British Journal of Haematology

1 reference

Europe PubMed Central

2 August 2017

169

1 reference

Europe PubMed Central

2 August 2017

4

1 reference

Europe PubMed Central

2 August 2017

534-543

1 reference

Europe PubMed Central

2 August 2017

The development of proteasome inhibitors as anticancer drugs

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Deregulated degradation of the cdk inhibitor p27 and malignant transformation.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Cullin-based ubiquitin ligase and its control by NEDD8-conjugating system

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture).

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Skp2 is oncogenic and overexpressed in human cancers

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Ubiquitin and ubiquitin-like proteins in protein regulation

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Nuclear factor-kappaB in cancer development and progression

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Function and regulation of cullin-RING ubiquitin ligases

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Nedd8 modification of cul-1 activates SCF(beta(TrCP))-dependent ubiquitination of IkappaBalpha

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Applications of pathology-assisted image analysis of immunohistochemistry-based biomarkers in oncology

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13323

21 January 2018

Identifiers

10.1111/BJH.13323

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34465347&oldid=1988022664"